Clinical Trial Update: Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update reports on the efficacy and safety of a cryopreserved formulation of OTL-101 in subjects with ADA-SCID, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency Due to Ada Deficiency

Drugs mentioned

• OTL-101

Snippet

Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust | Conditions: Severe Combined Immunodeficiency Due to ADA Deficiency | Phase 1, Phase 2 | Status: COMPLETED